Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

Jian L. Campian, Xiaobu Ye, Guneet Sarai, Joseph Herman, Stuart A Grossman

Research output: Contribution to journalArticle

Abstract

Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

Original languageEnglish (US)
JournalCancer Investigation
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Lymphopenia
Lymphocyte Count
Rectal Neoplasms
Blood Cell Count
Therapeutics
Observation
Survival
Neoplasms

Keywords

  • Lymphopenia
  • Radiation
  • Rectal cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer. / Campian, Jian L.; Ye, Xiaobu; Sarai, Guneet; Herman, Joseph; Grossman, Stuart A.

In: Cancer Investigation, 01.01.2018.

Research output: Contribution to journalArticle

@article{eff3ed8788124bdd900c6fd8da7996d9,
title = "Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer",
abstract = "Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35{\%} of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.",
keywords = "Lymphopenia, Radiation, Rectal cancer",
author = "Campian, {Jian L.} and Xiaobu Ye and Guneet Sarai and Joseph Herman and Grossman, {Stuart A}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/07357907.2018.1499028",
language = "English (US)",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Severe Treatment-Related Lymphopenia in Patients with Newly Diagnosed Rectal Cancer

AU - Campian, Jian L.

AU - Ye, Xiaobu

AU - Sarai, Guneet

AU - Herman, Joseph

AU - Grossman, Stuart A

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

AB - Background: Although treatment-related lymphopenia (TRL) is common in many cancers no data exists in rectal cancer. Methods: Serial lymphocyte counts were analyzed retrospectively in patients with newly diagnosed rectal cancer, serial blood counts, and complete records at Johns Hopkins Hospital. Results: Fifty-seven patients with normal pretreatment lymphocyte counts were studied. Two months after beginning chemoradiation, 35% of these patients developed grade III-IV lymphopenia [median lymphocyte counts fell from 1590 to 490 cell/mm3 (p < 0.001)] which persisted throughout one year of observation. Conclusion: Severe and prolonged TRL is common in rectal cancer. Further studies are required to determine TRL’s relationship to survival.

KW - Lymphopenia

KW - Radiation

KW - Rectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85052156287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052156287&partnerID=8YFLogxK

U2 - 10.1080/07357907.2018.1499028

DO - 10.1080/07357907.2018.1499028

M3 - Article

C2 - 30095290

AN - SCOPUS:85052156287

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

ER -